These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16462689)

  • 1. [Management strategies for major depressive episodes as a function of initial response to an SSRI or SNRI antidepressant: results of the ORACLE survey].
    Spadone C; Sylvestre M; Chiarelli P; Richard-Berthe C
    Encephale; 2005; 31(6 Pt 1):698-704. PubMed ID: 16462689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patients with a complete or partial remission of Major Depressive Episode as part of Recurrent Major Depressive Disorder: description of ECLAIR study population].
    Gérard A; Pélissolo A; Falissard B; Goussiaume G; Millet V
    Encephale; 2005; 31(2):174-81. PubMed ID: 15959444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors.
    López-Muñoz F; Alamo C; Rubio G; García-García P; Pardo A
    Pharmacopsychiatry; 2007 Jan; 40(1):14-9. PubMed ID: 17327955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of remission in 208 drug-resistant depressive patients treated with electroconvulsive therapy.
    Medda P; Mauri M; Toni C; Mariani MG; Rizzato S; Miniati M; De Simone L; Perugi G
    J ECT; 2014 Dec; 30(4):292-7. PubMed ID: 24625706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
    Iosifescu DV; Nierenberg AA; Mischoulon D; Perlis RH; Papakostas GI; Ryan JL; Alpert JE; Fava M
    J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.
    Kato M; Takekita Y; Koshikawa Y; Sakai S; Bandou H; Nishida K; Sunada N; Onohara A; Hatashita Y; Serretti A; Kinoshita T
    J Psychiatr Res; 2017 Jun; 89():97-104. PubMed ID: 28213170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    Ninan PT; Hassman HA; Glass SJ; McManus FC
    J Clin Psychiatry; 2004 Mar; 65(3):414-20. PubMed ID: 15096082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors.
    Konuk N; Atasoy N; Atik L; Akay O
    Adv Ther; 2006; 23(4):646-54. PubMed ID: 17050507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
    Gilmer WS; Gollan JK; Wisniewski SR; Howland RH; Trivedi MH; Miyahara S; Fleck J; Thase ME; Alpert JE; Nierenberg AA; Warden D; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Aug; 69(8):1246-56. PubMed ID: 18681756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.